Clinical trial · Interventional
Evaluation of PET/MRI in Patients With Pancreatic Adenocarcinoma
Evaluation of the Novel Imaging Modality Simultaneous Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI) in Patients With Pancreatic Adenocarcinoma
NCT02028377CI-TRIAL-00033395completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will use PET/MRI in patients with adenocarcinoma of the pancreas to identify hidden metastatic disease or identify patients with borderline or locally advanced disease.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adenocarcinoma Pancreas | Pancreatic Adenocarcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PET/MRI | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Imaging
- description
- PET/MRI
- interventionNames
- Procedure: PET/MRI
Primary outcomes (1)
- measure
- PET/MRI compared to conventional CT and MRI
- timeFrame
- Up to several months or longer. Patient will undergo research imaging with each standard of care scan they have.
- description
- Primary outcome is to determine if the primary tumor and the margins of anatomical land marks from the PET/MRI imaging is more precise and gives a clearer picture of tumor location than standard care, CT or MRI. Both standard of care imaging and this new technology will be compared to the final pathologic analysis, measuring the true distance (in mm) between the primary tumor and margins. Data will be reported as mm.
Secondary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Presence of suspicious lesion of the pancreas consistent with pancreatic adenocarcinoma. Cytological confirmation is not required. * Patients preparing to receive therapy for pancreas cancer, including patients enrolled in NCT01413022 * Patient must be 18 years or older * Patient must have a life expectancy of more than 6 months and performance status of 2 or less * Patient must be able to understand and willing to sign an approved written informed consent document * Women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the length of the study * Patients enrolled in the Clinical trials.gov# NCT01413022 trial must meet both studies eligibility criteria. Exclusion Criteria: * Patient must not have had prior resection for pancreatic adenocarcinoma. * Patient must not have a history of other malignancy less than or equal to 5 years previous with the exception of basal cell or squamous cell carcinoma of the skin which were treated with local resection only or carcinoma in situ of the cervix * Patient must not be unable to receive a PET-MRI scan due to renal function, allergy or other problem with receiving or tolerating an MRI scan, etc. All patients will fill out a standard MRI screening form. * Patients must not have a blood glucose of greater than or equal to 200mg/dL at the time of PET-MRI or if a patient is diabetic and glucose is not controlled. At the discretion of the PI and the authorized user and with their approval prior to 2-\[18\]fluoro-2-deoxy-D-glucose (FDG) injection, patients with blood glucose ≥ 200 mg/dL may participate in the study. * Patient must not be pregnant and/or breast feeding
References
Publications (0)
Data not yet available
No reference posted for this study.